Cisplatin and docetaxel (DP), cisplatin and vinorelbine (CV), calboplatin and paclitaxel (CbP) are optimal regimens for locally advanced non-small-cell lung cancer (LA-NSCLC).Patients and methods
We retrospectively analyzed the effectiveness and safety of DP, CV and CbP with the concurrent thoracic radiotherapy (TRT) in patients with unresectable LA-NSCLC between August 2005 and August 2011.Results
We identified 76 patients. DP/CV/CbP were undergone in 25/44/7 patients. The median age was 68 years (37–74); male/female, 57/19; PS 0/1, 46/33; Ad/Sq/NOS, 41/29/14; and clinical stage IIB/IIIA/IIIB, 4/32/40. Dose delivery of chemotherapy was 88/92/80% (DP/CV/CbP) and that of TRT was 93/92/99%. Sixty-three patients responded to the therapy, including five CR (2/3/0), 58 PR (19/33/6). Forty-four patients had recurrence (12/27/5). Among them, 21 patients recurred at a local site (8/10/3) and 23 patients at a distant site (4/17/2). Of this, 45 patients developed grade 3 or greater hematological toxicities (10/33/2). Non-hematological toxicities were grade 3 radiation esophagitis in four patients (2/1/1) and grade 3 radiation pneumonitis in seven patients (2/3/2), respectively.Discussion
The efficacy, dose delivery and safety in DP and CV arms were similar to previous trials.